MX2018011951A - Metodo para seleccionar proteinas recombinantes ricas en m6p. - Google Patents

Metodo para seleccionar proteinas recombinantes ricas en m6p.

Info

Publication number
MX2018011951A
MX2018011951A MX2018011951A MX2018011951A MX2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A
Authority
MX
Mexico
Prior art keywords
recombinant human
selection
human lysosomal
recombinant proteins
lysosomal proteins
Prior art date
Application number
MX2018011951A
Other languages
English (en)
Inventor
Gotschall Russell
V Do Hung
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2018011951A publication Critical patent/MX2018011951A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Water Supply & Treatment (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Métodos para producir, capturar y purificar proteínas lisosomales humanas recombinantes. Estas proteínas lisosomales humanas recombinantes pueden tener un contenido elevado de residuos de manosa-6-fosfato. Composiciones farmacéuticas que comprenden estas proteínas lisosomales humanas recombinantes. Métodos de tratamiento. Usos de estas proteínas lisosomales humanas recombinantes.
MX2018011951A 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p. MX2018011951A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662315400P 2016-03-30 2016-03-30
US201762457584P 2017-02-10 2017-02-10
US15/473,994 US10227577B2 (en) 2016-03-30 2017-03-30 Method for selection of high M6P recombinant proteins
PCT/US2017/024981 WO2017173059A1 (en) 2016-03-30 2017-03-30 Method for selection of high m6p recombinant proteins

Publications (1)

Publication Number Publication Date
MX2018011951A true MX2018011951A (es) 2019-02-13

Family

ID=58640993

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018011951A MX2018011951A (es) 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014533A MX2022014533A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022014533A MX2022014533A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Country Status (13)

Country Link
US (3) US10227577B2 (es)
JP (3) JP7046003B2 (es)
KR (3) KR102343162B1 (es)
AU (2) AU2017239640B2 (es)
BR (1) BR112018070189A2 (es)
CA (1) CA3019354A1 (es)
CL (1) CL2018002767A1 (es)
IL (2) IL262060B (es)
MX (3) MX2018011951A (es)
PE (1) PE20190127A1 (es)
SG (1) SG11201808592PA (es)
WO (1) WO2017173059A1 (es)
ZA (2) ZA201807184B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512676B2 (en) * 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
HUE062504T2 (hu) * 2017-05-15 2023-11-28 Amicus Therapeutics Inc Rekombináns humán savas alfa-glükozidáz
EP4025242A1 (en) 2019-09-06 2022-07-13 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202400212A (zh) 2022-05-05 2024-01-01 美商阿米庫斯醫療股份有限公司 用於治療龐貝氏病之方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020073438A1 (en) * 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020013953A1 (en) * 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
EP1030839B1 (en) 1997-11-10 2004-02-04 G.D. SEARLE & CO. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU3113700A (en) 1998-12-07 2000-06-26 Genzyme Corporation Treatment of pompe's disease
ATE402701T1 (de) 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
EP1196190B1 (en) 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
PT1782825E (pt) 2000-07-18 2014-11-04 Univ Duke Tratamento de doenças de armazenanto de glicogénio tipo ii
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
JP2005523882A (ja) 2001-10-16 2005-08-11 アールエックスキネティックス，インコーポレイテッド 高濃度タンパク質製剤および製造の方法
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
SI2332567T1 (sl) 2003-01-31 2015-08-31 The Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2005077093A2 (en) * 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
US20050244400A1 (en) 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
KR20080025373A (ko) 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법
JP2010509344A (ja) 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
WO2009066069A1 (en) 2007-11-21 2009-05-28 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
ES2541933T3 (es) * 2008-02-12 2015-07-28 Amicus Therapeutics, Inc. Método para predecir la respuesta al tratamiento farmacológico con chaperona de enfermedades
AU2009223125A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for Pompe disease
CA2718182A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US20100119502A1 (en) 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
WO2010118283A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
CN104651428A (zh) * 2009-09-29 2015-05-27 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
CN103328646B (zh) * 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法
KR20140037082A (ko) 2011-04-22 2014-03-26 겐자임 코포레이션 가속 가공으로 변형된 산 알파 글루코시다제
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
JP6320931B2 (ja) 2011-12-22 2018-05-09 セントジーン アイピー ゲーエムベーハー リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
US9249399B2 (en) * 2012-03-15 2016-02-02 Oxyrane Uk Limited Methods and materials for treatment of pompe's disease
DK2844279T3 (da) 2012-05-03 2021-03-15 Amicus Therapeutics Inc Doseringsprogrammer til behandling af pompes sygdom
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
ES2967620T3 (es) * 2014-09-30 2024-05-03 Amicus Therapeutics Inc Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins

Also Published As

Publication number Publication date
JP2022101545A (ja) 2022-07-06
BR112018070189A2 (pt) 2019-02-19
ZA202006604B (en) 2023-04-26
US10227577B2 (en) 2019-03-12
AU2017239640B2 (en) 2022-07-28
US11441138B2 (en) 2022-09-13
US20230079225A1 (en) 2023-03-16
MX2022014532A (es) 2022-12-13
KR102455821B1 (ko) 2022-10-18
IL295551A (en) 2022-10-01
IL262060A (en) 2018-11-29
ZA201807184B (en) 2021-02-24
KR102343162B1 (ko) 2021-12-23
MX2022014533A (es) 2022-12-13
JP7436545B2 (ja) 2024-02-21
AU2017239640A1 (en) 2018-10-25
US20190382742A1 (en) 2019-12-19
KR20210157477A (ko) 2021-12-28
KR20220145918A (ko) 2022-10-31
IL262060B (en) 2022-09-01
AU2022259797A1 (en) 2022-12-01
JP7046003B2 (ja) 2022-04-01
JP2024063015A (ja) 2024-05-10
JP2019509754A (ja) 2019-04-11
PE20190127A1 (es) 2019-01-17
WO2017173059A1 (en) 2017-10-05
US20170335301A1 (en) 2017-11-23
CA3019354A1 (en) 2017-10-05
SG11201808592PA (en) 2018-10-30
KR20180128945A (ko) 2018-12-04
CL2018002767A1 (es) 2019-01-11

Similar Documents

Publication Publication Date Title
MX2022014532A (es) Metodo para seleccionar proteinas recombinantes ricas en m6p.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
MY187486A (en) Cysteine protease
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2018011162A (es) Metodos de purificacion de colageno 7.
WO2015161243A3 (en) Beta-lactamases with improved properties for therapy
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
NZ728401A (en) High purity oritavancin and method of producing same
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
MX2019013458A (es) Disminucion de homocisteina mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2018009676A (es) Proceso.